FY2025 EPS Forecast for Kura Oncology Reduced by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Investment analysts at Brookline Capital Management dropped their FY2025 EPS estimates for Kura Oncology in a report released on Monday, January 12th. Brookline Capital Management analyst L. Cann now expects that the company will earn ($2.90) per share for the year, down from their prior estimate of ($2.87). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Brookline Capital Management also issued estimates for Kura Oncology’s Q4 2025 earnings at ($0.65) EPS.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. The company had revenue of $20.75 million during the quarter, compared to the consensus estimate of $17.48 million.

Several other equities analysts have also recently weighed in on KURA. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a report on Wednesday, October 8th. Wedbush restated an “outperform” rating and issued a $38.00 price target (up previously from $36.00) on shares of Kura Oncology in a research report on Friday, November 14th. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a research report on Tuesday. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a report on Friday, December 5th. Finally, UBS Group upped their price target on shares of Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, November 14th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.00.

Kura Oncology Trading Up 0.4%

Shares of KURA stock opened at $9.21 on Wednesday. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $801.45 million, a price-to-earnings ratio of -3.71 and a beta of 0.25. Kura Oncology has a 12-month low of $5.41 and a 12-month high of $12.49. The stock’s 50-day moving average price is $10.69 and its 200-day moving average price is $8.86.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KURA. Vanguard Group Inc. increased its holdings in shares of Kura Oncology by 2.2% during the 3rd quarter. Vanguard Group Inc. now owns 5,468,522 shares of the company’s stock worth $48,396,000 after buying an additional 120,197 shares during the last quarter. EcoR1 Capital LLC lifted its stake in Kura Oncology by 59.1% in the second quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock worth $24,234,000 after acquiring an additional 1,559,702 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in Kura Oncology by 101.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after buying an additional 1,121,228 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Kura Oncology by 11.7% in the second quarter. Geode Capital Management LLC now owns 2,014,029 shares of the company’s stock valued at $11,623,000 after purchasing an additional 211,470 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its position in shares of Kura Oncology by 63.0% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after buying an additional 738,761 shares during the last quarter.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, insider Brian T. Powl sold 8,887 shares of Kura Oncology stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $11.18, for a total transaction of $99,356.66. Following the completion of the sale, the insider directly owned 139,689 shares in the company, valued at approximately $1,561,723.02. The trade was a 5.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Teresa Brophy Bair sold 8,804 shares of the firm’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $11.18, for a total value of $98,428.72. Following the sale, the insider directly owned 188,139 shares in the company, valued at approximately $2,103,394.02. This trade represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 68,343 shares of company stock valued at $730,858. Corporate insiders own 6.40% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.